ArticleExperimental hematology2024

In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts.

Joanna Randall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.